<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00425906</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000526182</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC03C2</secondary_id>
    <secondary_id>1217-03</secondary_id>
    <nct_id>NCT00425906</nct_id>
  </id_info>
  <brief_title>Nicotine in Treating &quot;Hunger Pain&quot; in Patients With Malignant Bowel Obstruction Caused By Cancer</brief_title>
  <official_title>A Pilot Study of Nicotine for &quot;Hunger Pain&quot; in Patients With Bowel Obstruction From Incurable Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The use of a nicotine inhaler may help decrease appetite and relieve &quot;hunger pain&quot;&#xD;
      (an intense craving for food) in patients with malignant bowel obstruction caused by cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying the side effects and how well a nicotine&#xD;
      inhaler works in treating &quot;hunger pain&quot; in patients with malignant bowel obstruction caused&#xD;
      by cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether patients with malignant bowel obstruction due to incurable cancer&#xD;
           utilize a potential therapy for &quot;hunger pain.&quot;&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy and toxicity of nicotine in treating &quot;hunger&#xD;
           pain&quot; in these patients.&#xD;
&#xD;
        -  Determine whether nicotine results in a decline in circulating ghrelin (for patients&#xD;
           enrolled at the Mayo Rochester Clinic only).&#xD;
&#xD;
        -  Evaluate hormonal changes in patients treated with nicotine (for patients enrolled at&#xD;
           the Mayo Rochester Clinic only).&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter, pilot study.&#xD;
      Patients are stratified according to vomiting status within the past 24 hours (yes vs no) and&#xD;
      use of narcotics (yes vs no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive a nicotine inhaler to use as needed for &quot;hunger pain.&quot; Treatment&#xD;
           continues for up to 48 hours in the absence of unacceptable toxicity .&#xD;
&#xD;
        -  Arm II: Patients receive a placebo inhaler to use as needed for &quot;hunger pain.&quot; Treatment&#xD;
           continues for up to 48 hours in the absence of unacceptable toxicity.&#xD;
&#xD;
      After 48 hours, patients in arm I may continue nicotine therapy off study. Patients in arm II&#xD;
      who are not surgical candidates may cross over to treatment with the nicotine inhaler off&#xD;
      study.&#xD;
&#xD;
      Blood and spot urine samples are collected at baseline and after 48 hours from patients&#xD;
      enrolled at the Mayo Rochester Clinic. Blood samples are analyzed to evaluate circulating&#xD;
      hormone (e.g., ghrelin, leptin) concentrations. Urine samples are analyzed to evaluate&#xD;
      nicotine and nicotine metabolite concentrations.&#xD;
&#xD;
      Global quality of life is assessed at baseline and after 48 hours. &quot;Hunger pain&quot; is assessed&#xD;
      at baseline.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patient enrollment occurred.&#xD;
  </why_stopped>
  <start_date>December 2003</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of whether ≥ 50% of patients utilize nicotine for treating &quot;hunger pain&quot; ≥ 2 times over a 48-hour period</measure>
    <time_frame>48 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTCAE v 2.0</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global quality of life</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hunger assessment</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating hormonal concentrations (for patients enrolled at the Mayo Rochester Clinic only)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Anorexia</condition>
  <condition>Constipation, Impaction, and Bowel Obstruction</condition>
  <condition>Pain</condition>
  <condition>Psychosocial Effects of Cancer and Its Treatment</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Nicotine inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo inhaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine</intervention_name>
    <arm_group_label>Nicotine inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality of life</intervention_name>
    <arm_group_label>Nicotine inhaler</arm_group_label>
    <arm_group_label>Placebo inhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of any incurable malignancy&#xD;
&#xD;
          -  Presence of malignant bowel obstruction&#xD;
&#xD;
          -  Must be on strict &quot;nothing per os&quot; (NPO) status over the next 48 hours&#xD;
&#xD;
               -  Ice chips allowed&#xD;
&#xD;
          -  Acknowledges that &quot;hunger pain&quot; is a problem&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Mentally competent&#xD;
&#xD;
          -  No history of life-threatening arrhythmia&#xD;
&#xD;
          -  No severe or worsening angina&#xD;
&#xD;
          -  No accelerated hypertension&#xD;
&#xD;
          -  No known hypersensitivity to nicotine&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Concurrent short-term use of dexamethasone or other hormonal therapy or symptom&#xD;
             control strategy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aminah Jatoi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerardo Colon-Otero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>January 19, 2007</study_first_submitted>
  <study_first_submitted_qc>January 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2007</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <name_title>Aminah Jatoi, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>psychosocial effects of cancer and its treatment</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>constipation, impaction, and bowel obstruction</keyword>
  <keyword>anorexia</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Obstruction</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Anorexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

